Microcap Ledger CVRx, Inc. $CVRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Minneapolis, MN
- Fiscal year end
- December 31
- Shares outstanding
- 26,641,597 [10-Q 2026-08-06]
What the company doesAI summary of filing
CVRx is a commercial-stage medical device company that develops and sells Barostim, an implantable neuromodulation device for treating heart failure with reduced ejection fraction (HFrEF). Barostim delivers electrical pulses to baroreceptors in the carotid artery to counteract autonomic nervous system imbalance that contributes to heart failure progression. The company sells primarily to hospitals in the U.S. and select European countries through direct sales and distributors, generating revenue of $56.7 million in 2025 with an 85% gross margin, though it reported a net loss of $53.3 million. Barostim received FDA approval in 2019 and expanded labeling approval in 2023 based on clinical trial data demonstrating symptomatic improvements in exercise capacity, quality of life, and functional status for eligible HFrEF patients. [10-K 2026-02-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $30.47M | −$27.16M | −$20.99M | $64.59M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $56.65M | −$53.31M | −$40.17M | $75.71M | [10-K 2026-02-13] |
| FY ended Dec 2024 | $51.29M | −$59.97M | −$39.14M | $105.93M | [10-K 2026-02-13] |
- Quarterly cash burn
- −$10.49M
- Cash runway Estimate
- ~18.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-25 | 24,263,663 | [10-Q 2024-11-01] |
| 2025-02-11 | 26,036,032 | [10-K 2025-02-18] |
| 2025-05-02 | 26,072,599 | [10-Q 2025-05-09] |
| 2025-07-29 | 26,151,724 | [10-Q 2025-08-05] |
| 2025-10-30 | 26,210,109 | [10-Q 2025-11-06] |
| 2026-02-06 | 26,311,607 | [10-K 2026-02-13] |
| 2026-05-05 | 26,535,944 | [10-Q 2026-05-12] |
| 2026-07-30 | 26,641,597 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-11-06; declared effective 2025-12-15 [S-3 2025-11-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-13 | Binkowski Brent | buy | 26,223 | $2.91 | [4 2026-08-13] |
| 2026-08-12 | Binkowski Brent | sell | 1,309 | $2.55 | [4 2026-08-13] |
| 2026-06-01 | Nielsen Kirk G. | grant | 8,720 | — | [4 2026-06-03] |
| 2026-06-01 | Jain Mudit K. | grant | 8,720 | — | [4 2026-06-03] |
| 2026-06-01 | Slattery Joseph P | grant | 8,720 | — | [4 2026-06-03] |
| 2026-06-01 | Hill, Mitch C. | grant | 8,720 | — | [4 2026-06-03] |
| 2026-06-01 | Ballinger Kevin J. | grant | 8,720 | — | [4 2026-06-03] |
| 2026-06-01 | Shadan Martha | grant | 8,720 | — | [4 2026-06-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-21 | 8-K | Director or officer change |
| 2026-08-24 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Director or officer change |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-09 | 8-K | Director or officer change |
| 2026-06-03 | 8-K | Shareholder vote results |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations |
| 2026-04-20 | DEF 14A | Proxy statement |
Alerts for $CVRX
Email me when CVRx, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.